129 related articles for article (PubMed ID: 16269198)
1. Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity.
Mrkvan T; Sirova M; Etrych T; Chytil P; Strohalm J; Plocova D; Ulbrich K; Rihova B
J Control Release; 2005 Dec; 110(1):119-29. PubMed ID: 16269198
[TBL] [Abstract][Full Text] [Related]
2. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting.
Etrych T; Chytil P; Mrkvan T; Sírová M; Ríhová B; Ulbrich K
J Control Release; 2008 Dec; 132(3):184-92. PubMed ID: 18534705
[TBL] [Abstract][Full Text] [Related]
3. The same drug but a different mechanism of action: comparison of free doxorubicin with two different N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugates in EL-4 cancer cell line.
Kovár L; Strohalm J; Chytil P; Mrkvan T; Kovár M; Hovorka O; Ulbrich K; Ríhová B
Bioconjug Chem; 2007; 18(3):894-902. PubMed ID: 17402705
[TBL] [Abstract][Full Text] [Related]
4. HPMA copolymers containing doxorubicin bound by a proteolytically or hydrolytically cleavable bond: comparison of biological properties in vitro.
Kovár M; Kovár L; Subr V; Etrych T; Ulbrich K; Mrkvan T; Loucká J; Ríhová B
J Control Release; 2004 Sep; 99(2):301-14. PubMed ID: 15380639
[TBL] [Abstract][Full Text] [Related]
5. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
Etrych T; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
[TBL] [Abstract][Full Text] [Related]
6. Tumor targeting by pH-sensitive, biodegradable, cross-linked N-(2-hydroxypropyl) methacrylamide copolymer micelles.
Zhou Z; Li L; Yang Y; Xu X; Huang Y
Biomaterials; 2014 Aug; 35(24):6622-35. PubMed ID: 24814427
[TBL] [Abstract][Full Text] [Related]
7. Polymeric anticancer drugs with pH-controlled activation.
Ulbrich K; Etrych T; Chytil P; Pechar M; Jelinkova M; Rihova B
Int J Pharm; 2004 Jun; 277(1-2):63-72. PubMed ID: 15158969
[TBL] [Abstract][Full Text] [Related]
8. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.
David A; Kopecková P; Minko T; Rubinstein A; Kopecek J
Eur J Cancer; 2004 Jan; 40(1):148-57. PubMed ID: 14687799
[TBL] [Abstract][Full Text] [Related]
9. Using small-angle neutron scattering to study the solution conformation of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates.
Paul A; Vicent MJ; Duncan R
Biomacromolecules; 2007 May; 8(5):1573-9. PubMed ID: 17419585
[TBL] [Abstract][Full Text] [Related]
10. Synergistic enhancement of anticancer therapeutic efficacy of HPMA copolymer doxorubicin conjugates via combination of ligand modification and stimuli-response srategies.
Li L; Zhou M; Huang Y
Int J Pharm; 2018 Jan; 536(1):450-458. PubMed ID: 29237570
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of linear HPMA-doxorubicin conjugates with pH-sensitive drug release: efficacy, safety, and immunomodulating activity in murine model.
Sirova M; Mrkvan T; Etrych T; Chytil P; Rossmann P; Ibrahimova M; Kovar L; Ulbrich K; Rihova B
Pharm Res; 2010 Jan; 27(1):200-8. PubMed ID: 19894105
[TBL] [Abstract][Full Text] [Related]
12. Interaction of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates with human liver microsomal cytochromes P450: comparison with free doxorubicin.
Masek V; Anzenbacherová E; Etrych T; Strohalm J; Ulbrich K; Anzenbacher P
Drug Metab Dispos; 2011 Sep; 39(9):1704-10. PubMed ID: 21642392
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences.
Ríhová B; Strohalm J; Hovorka O; Subr V; Etrych T; Chytil P; Pola R; Plocová D; Boucek J; Ulbrich K
J Control Release; 2008 Apr; 127(2):110-20. PubMed ID: 18325618
[TBL] [Abstract][Full Text] [Related]
14. Highly effective anti-tumor nanomedicines based on HPMA copolymer conjugates with pirarubicin prepared by controlled RAFT polymerization.
Randárová E; Nakamura H; Islam R; Studenovský M; Mamoru H; Fang J; Chytil P; Etrych T
Acta Biomater; 2020 Apr; 106():256-266. PubMed ID: 32058082
[TBL] [Abstract][Full Text] [Related]
15. Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-amino ester) block copolymer micelles for cancer therapy.
Ko J; Park K; Kim YS; Kim MS; Han JK; Kim K; Park RW; Kim IS; Song HK; Lee DS; Kwon IC
J Control Release; 2007 Nov; 123(2):109-15. PubMed ID: 17894942
[TBL] [Abstract][Full Text] [Related]
16. Passive and active hepatoma tumor targeting of new N-(2-hydroxypropyl)methacrylamide copolymer conjugates: synthesis, characterization, and evaluation in vitro and in vivo.
Yuan J; Yuan B; Guo H; Zeng X; Wang X; Liao S; Li J; Jia Z; Song F; Wang F
J Biomater Sci Polym Ed; 2013; 24(12):1472-83. PubMed ID: 23829459
[TBL] [Abstract][Full Text] [Related]
17. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate.
Omelyanenko V; Kopecková P; Gentry C; Kopecek J
J Control Release; 1998 Apr; 53(1-3):25-37. PubMed ID: 9741911
[TBL] [Abstract][Full Text] [Related]
18. HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity.
Etrych T; Subr V; Strohalm J; Sírová M; Ríhová B; Ulbrich K
J Control Release; 2012 Dec; 164(3):346-54. PubMed ID: 22759979
[TBL] [Abstract][Full Text] [Related]
19. Peptide-directed HPMA copolymer-doxorubicin conjugates as targeted therapeutics for colorectal cancer.
Kopansky E; Shamay Y; David A
J Drug Target; 2011 Dec; 19(10):933-43. PubMed ID: 22074249
[TBL] [Abstract][Full Text] [Related]
20. Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic.
Duncan R; Gac-Breton S; Keane R; Musila R; Sat YN; Satchi R; Searle F
J Control Release; 2001 Jul; 74(1-3):135-46. PubMed ID: 11489490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
